MediWound (NASDAQ:MDWD) Stock Price Passes Below 200-Day Moving Average of $4.29

MediWound Ltd. (NASDAQ:MDWD) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.29 and traded as low as $3.45. MediWound shares last traded at $3.46, with a volume of 155,728 shares traded.

Several research firms have issued reports on MDWD. Zacks Investment Research upgraded shares of MediWound from a “sell” rating to a “hold” rating in a research note on Friday, August 13th. HC Wainwright decreased their price objective on shares of MediWound from $7.00 to $6.50 and set a “buy” rating for the company in a research note on Wednesday, August 11th. Aegis decreased their price objective on shares of MediWound from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, August 17th. Finally, Oppenheimer reiterated a “buy” rating and set a $7.00 price objective on shares of MediWound in a research note on Thursday, June 10th.

The firm has a market capitalization of $94.24 million, a PE ratio of -9.89 and a beta of 1.54. The firm’s 50 day moving average price is $3.75 and its two-hundred day moving average price is $4.29.

MediWound (NASDAQ:MDWD) last announced its earnings results on Tuesday, August 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). MediWound had a negative net margin of 38.43% and a negative return on equity of 171.14%. Equities analysts expect that MediWound Ltd. will post -0.47 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley raised its holdings in MediWound by 88.5% in the second quarter. Morgan Stanley now owns 76,450 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 35,898 shares in the last quarter. Meitav Dash Investments Ltd. raised its holdings in MediWound by 198.5% in the second quarter. Meitav Dash Investments Ltd. now owns 30,493 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 20,279 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in MediWound in the second quarter valued at $65,000. PDT Partners LLC acquired a new stake in MediWound in the second quarter valued at $47,000. Finally, Toroso Investments LLC acquired a new stake in MediWound in the second quarter valued at $66,000. 13.98% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound (NASDAQ:MDWD)

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Read More: Dollar Cost Averaging

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.